Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib
- Authors
- Gerken, G.; Zhu, A.; Kang, Y-K; Yen, C-J; Finn, R.; Galle, P.; Llovet, J.; Assenat, E.; Brandi, G.; Lim, H. Y.; Pracht, M.; Rau, K-M; Merle, P.; Motomura, K.; Ohno, I; Daniele, B.; Shin, D. B.; Abada, P. B.; Hsu, Y.; Kudo, M.
- Issue Date
- 2018
- Publisher
- KARGER
- Citation
- ONCOLOGY RESEARCH AND TREATMENT, v.41, pp.253 - 254
- Journal Title
- ONCOLOGY RESEARCH AND TREATMENT
- Volume
- 41
- Start Page
- 253
- End Page
- 254
- ISSN
- 2296-5270
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.